Table 2.
Patient Characteristics at the Baseline Test, Stratified by the Type of Diagnosed Cancer and Infection Group
| AIDS-Defining Cancers | Non–AIDS-Defining Cancers | Free of Cancer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaposi Sarcoma | Cervical Cancer | Non-Hodgkin Lymphoma | HPV Relateda | Epstein-Barr Virus Relatedb | Conjunctival Cancer | Liver and Bile Duct Cancer | Stomach Cancer | Bladder Cancer | Infection Unrelated (See Table 3) | ||
| n | 2262 | 4150 | 1060 | 692 | 288 | 604 | 94 | 164 | 112 | 5182 | 3 517 188 |
| Female | 1256 (55.5) | 4150 (100.0) | 621 (58.6) | 487 (70.4) | 152 (52.8) | 402 (66.6) | 47 (50.0) | 77 (47.0) | 49 (43.8) | 3381 (65.2) | 2 509 847 (71.4) |
| Median [IQR] age, years | 32.51 [27.37, 38.52] | 38.62 [32.73, 45.77] | 36.19 [30.25, 42.96] | 36.64 [30.63, 45.10] | 33.56 [28.04, 39.27] | 35.14 [30.47, 40.80] | 44.26 [35.02, 51.36] | 45.04 [37.99, 53.86] | 50.15 [41.24, 57.21] | 44.79 [36.16, 52.68] | 33.65 [27.55, 41.17] |
| Calendar period | |||||||||||
| 2004–2007 | 1116 (49.3) | 1932 (46.6) | 511 (48.2) | 313 (45.2) | 150 (52.1) | 280 (46.4) | 42 (44.7) | 68 (41.5) | 46 (41.1) | 2388 (46.1) | 744 684 (21.2) |
| 2008–2011 | 1025 (45.3) | 1988 (47.9) | 491 (46.3) | 330 (47.7) | 122 (42.4) | 287 (47.5) | 49 (52.1) | 85 (51.8) | 57 (50.9) | 2491 (48.1) | 1 999 166 (56.8) |
| 2012–2014 | 121 (5.3) | 230 (5.5) | 58 (5.5) | 49 (7.1) | 16 (5.6) | 37 (6.1) | 3 (3.2) | 11 (6.7) | 9 (8.0) | 303 (5.8) | 773 338 (22.0) |
| Median [IQR] CD4 cell count (cells/µL) | 256 [137, 389] | 263 [139, 420] | 221 [112, 355] | 200 [105, 348] | 253 [150, 422] | 179 [87, 302] | 219 [128, 380] | 263 [155, 464] | 289 [151, 425] | 264 [139, 422] | 292 [164, 453] |
| CD4 cell count (cells/µL) | |||||||||||
| <50 | 168 (7.4) | 267 (6.4) | 81 (7.6) | 58 (8.4) | 15 (5.2) | 60 (9.9) | 10 (10.6) | 16 (9.8) | 8 (7.1) | 327 (6.3) | 198 893 (5.7) |
| 50–99 | 184 (8.1) | 336 (8.1) | 121 (11.4) | 84 (12.1) | 23 (8.0) | 94 (15.6) | 4 (4.3) | 10 (6.1) | 5 (4.5) | 412 (8.0) | 237 854 (6.8) |
| 100–199 | 386 (17.1) | 740 (17.8) | 226 (21.3) | 156 (22.5) | 50 (17.4) | 136 (22.5) | 22 (23.4) | 25 (15.2) | 22 (19.6) | 961 (18.5) | 585 063 (16.6) |
| 200–349 | 633 (28.0) | 1011 (24.4) | 258 (24.3) | 150 (21.7) | 73 (25.3) | 143 (23.7) | 24 (25.5) | 42 (25.6) | 27 (24.1) | 1257 (24.3) | 906 471 (25.8) |
| 350–499 | 355 (15.7) | 630 (15.2) | 134 (12.6) | 81 (11.7) | 45 (15.6) | 61 (10.1) | 12 (12.8) | 20 (12.2) | 20 (17.9) | 788 (15.2) | 631 328 (17.9) |
| 500–699 | 178 (7.9) | 400 (9.6) | 67 (6.3) | 39 (5.6) | 30 (10.4) | 28 (4.6) | 12 (12.8) | 23 (14.0) | 12 (10.7) | 489 (9.4) | 409 079 (11.6) |
| ≥700 | 79 (3.5) | 208 (5.0) | 40 (3.8) | 28 (4.0) | 12 (4.2) | 9 (1.5) | 1 (1.1) | 9 (5.5) | 4 (3.6) | 281 (5.4) | 227 228 (6.5) |
| Missing | 279 (12.3) | 558 (13.4) | 133 (12.5) | 96 (13.9) | 40 (13.9) | 73 (12.1) | 9 (9.6) | 19 (11.6) | 14 (12.5) | 667 (12.9) | 321 272 (9.1) |
Data are presented as n or n (%) unless otherwise indicated.
Abbreviations: HPV, human papillomavirus; IQR, interquartile range.
aAnal, head and neck, penile, vaginal, vulvar cancer.
bHodgkin’s lymphoma, nasopharyngeal cancer.